Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Fig. 5

In vivo efficacy of D2C7-IT+αCTLA-4/αPD-1 combination therapies in bilateral subcutaneous CT-2A-dmEGFRvIII-Luc tumor-bearing C57BL/6 J mice. (a) The tumor growth curves are presented as SEM for the right treated tumors (upper panel) and left untreated tumors (lower panel). b and c Differences in left tumor volumes were assessed between the vehicle control group (G1) and all other treatment groups (G2–6) on Day 35 (b) and between D2C7-IT monotherapy group (G2) and D2C7-IT+αCTLA-4/αPD-1 combination therapy groups (G5–6) on Day 43 (c) and are not adjusted for multiple testing

Back to article page